SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the company will release second quarter 2004 financial results after the NASDAQ National Market closes on Tuesday, July 20, 2004. Arena also announced today that Jack Lief, President and Chief Executive Officer of Arena, will host a conference call to discuss the financial results and corporate highlights from the second quarter. The call will take place on Tuesday, July 20, 2004, at 5:00 PM Eastern Time (2:00 PM Pacific Time).
The conference call may be accessed by dialing (888) 273-9887 for domestic callers and (612) 332-0820 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals Second Quarter Earnings Conference Call." The conference call will be webcast live on Arena's website at http://www.arenapharm.com, under the investor relations section, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
Arena is a biopharmaceutical company focusing on the discovery, development and commercialization of drugs in four major therapeutic areas: metabolic, cardiovascular, central nervous system and inflammatory diseases. Arena is developing a broad pipeline of compounds including one in Phase 1 clinical trials for obesity and another in preclinical development for insomnia. The company's compounds act on an important class of drug targets called G protein-coupled receptors, or GPCRs, and were developed using Arena's proprietary technologies, including CART (Constitutively Activated Receptor Technology) and Melanophore. Arena also has research collaborations with Merck, Fujisawa, Taisho and TaiGen for products in a number of different indications. For additional information about Arena, please visit their website at http://www.arenapharm.com.
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, technologies, preclinical and clinical programs, future achievements, and statements that are not historical facts, including statements about Arena's ability to identify and develop drugs or which are preceded by the word "will" or similar words. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Important factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's SEC reports, including Arena's most recent quarterly report on Form 10-Q. These forward-looking statements represent Arena's judgment as of the date of this release. Arena disclaims any intent or obligation to update these forward-looking statements.
For further information please contact Jack Lief of Arena Pharmaceuticals, +1-858-453-7200, ext. 223; or Susan Neath of Atkins + Associates, +1-858-527-3486, for Arena Pharmaceuticals.
SOURCE Arena Pharmaceuticals, Inc.
Web site: http://www.arenapharm.com